XML 23 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Agreements (Details) (USD $)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Apr. 30, 2010
License Development And Commercialization Agreement With Takeda [Member]
Mar. 31, 2010
License Development And Commercialization Agreement With Takeda [Member]
Jun. 30, 2014
License Development And Commercialization Agreement With Takeda [Member]
Jun. 30, 2014
License Development And Commercialization Agreement With Takeda [Member]
Dec. 31, 2010
License Development And Commercialization Agreement With Takeda [Member]
Jun. 30, 2014
License Development And Commercialization Agreement With Takeda [Member]
Maximum [Member]
Jun. 30, 2014
License Development And Commercialization Agreement With Takeda [Member]
Upfront Payment And Non Substantive Milestone Payments Received [Member]
Jun. 30, 2014
License Development And Commercialization Agreement With Takeda [Member]
Product Shipped But Not Yet Sold [Member]
Jun. 30, 2014
Collaboration And Exclusive License Agreement With3 S Bio Inc [Member]
Dec. 31, 2008
Collaboration And Exclusive License Agreement With3 S Bio Inc [Member]
Collaborative Agreements                        
Upfront payment received     $ 60,000,000                 $ 1,000,000
Additional upfront payment             1,000,000          
Period of recognition of deferred revenues       10 years                
Milestone payments expected to be received under the agreement               186,000,000        
Deferred revenue recognized in earnings related to upfront payments         2,000,000 3,900,000         1,000,000  
Other reimbursement revenues         100,000 300,000            
Product sales and royalty revenue recognized         200,000 400,000            
Total upfront payments received                 61,000,000      
Total non-substantive milestone payments received                 18,000,000      
Deferred revenues                 45,400,000 2,200,000    
Deferred revenues, short-term 9,222,000 8,226,000             7,900,000 1,300,000    
Deferred revenues, long-term 38,360,000 44,534,000             37,500,000 900,000    
Deferred costs         2,000,000 2,000,000            
Deferred costs, short-term         1,200,000 1,200,000            
Deferred costs, long-term         $ 800,000 $ 800,000